Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indonesia investigates new H5N1 source, as case-fatality soars:

This article was originally published in Clinica

Executive Summary

Indonesia is investigating the source of exposure of a fatal case of H5N1 avian flu from Tangerang, Banten province, according to an August 16 WHO update, citing the health ministry. To date, of the country's 104 officially-confirmed cases, 83 (80%) have been fatal. Indonesia's case-fatality rate is increasing far above the average of other countries: of this year's 29 officially-recorded cases, 25 have been fatal, equating to 86% case-fatality. In the rest of the world, of this year's 29 cases, 11 were fatal (38%); and of the 217 cases recorded since 2003, 111 were fatal (51%).

You may also be interested in...

The Race Is On To Launch COVID-19 Antibody Home-Test In The UK

Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.

European CHMP Opinions and MAA Updates

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.

Pipeline Watch: Enhertu, Velexbru, Viltepso Approvals

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts